Tamoxifen for the treatment of myeloproliferative neoplasms : A Phase II clinical trial and exploratory analysis
© 2023. The Author(s)..
Current therapies for myeloproliferative neoplasms (MPNs) improve symptoms but have limited effect on tumor size. In preclinical studies, tamoxifen restored normal apoptosis in mutated hematopoietic stem/progenitor cells (HSPCs). TAMARIN Phase-II, multicenter, single-arm clinical trial assessed tamoxifen's safety and activity in patients with stable MPNs, no prior thrombotic events and mutated JAK2V617F, CALRins5 or CALRdel52 peripheral blood allele burden ≥20% (EudraCT 2015-005497-38). 38 patients were recruited over 112w and 32 completed 24w-treatment. The study's A'herns success criteria were met as the primary outcome ( ≥ 50% reduction in mutant allele burden at 24w) was observed in 3/38 patients. Secondary outcomes included ≥25% reduction at 24w (5/38), ≥50% reduction at 12w (0/38), thrombotic events (2/38), toxicities, hematological response, proportion of patients in each IWG-MRT response category and ELN response criteria. As exploratory outcomes, baseline analysis of HSPC transcriptome segregates responders and non-responders, suggesting a predictive signature. In responder HSPCs, longitudinal analysis shows high baseline expression of JAK-STAT signaling and oxidative phosphorylation genes, which are downregulated by tamoxifen. We further demonstrate in preclinical studies that in JAK2V617F+ cells, 4-hydroxytamoxifen inhibits mitochondrial complex-I, activates integrated stress response and decreases pathogenic JAK2-signaling. These results warrant further investigation of tamoxifen in MPN, with careful consideration of thrombotic risk.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Nature communications - 14(2023), 1 vom: 25. Nov., Seite 7725 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
094ZI81Y45 |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 13.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-023-43175-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364923342 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364923342 | ||
| 003 | DE-627 | ||
| 005 | 20240313233827.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-023-43175-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM364923342 | ||
| 035 | |a (NLM)38001082 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fang, Zijian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tamoxifen for the treatment of myeloproliferative neoplasms |b A Phase II clinical trial and exploratory analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Current therapies for myeloproliferative neoplasms (MPNs) improve symptoms but have limited effect on tumor size. In preclinical studies, tamoxifen restored normal apoptosis in mutated hematopoietic stem/progenitor cells (HSPCs). TAMARIN Phase-II, multicenter, single-arm clinical trial assessed tamoxifen's safety and activity in patients with stable MPNs, no prior thrombotic events and mutated JAK2V617F, CALRins5 or CALRdel52 peripheral blood allele burden ≥20% (EudraCT 2015-005497-38). 38 patients were recruited over 112w and 32 completed 24w-treatment. The study's A'herns success criteria were met as the primary outcome ( ≥ 50% reduction in mutant allele burden at 24w) was observed in 3/38 patients. Secondary outcomes included ≥25% reduction at 24w (5/38), ≥50% reduction at 12w (0/38), thrombotic events (2/38), toxicities, hematological response, proportion of patients in each IWG-MRT response category and ELN response criteria. As exploratory outcomes, baseline analysis of HSPC transcriptome segregates responders and non-responders, suggesting a predictive signature. In responder HSPCs, longitudinal analysis shows high baseline expression of JAK-STAT signaling and oxidative phosphorylation genes, which are downregulated by tamoxifen. We further demonstrate in preclinical studies that in JAK2V617F+ cells, 4-hydroxytamoxifen inhibits mitochondrial complex-I, activates integrated stress response and decreases pathogenic JAK2-signaling. These results warrant further investigation of tamoxifen in MPN, with careful consideration of thrombotic risk | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Janus Kinase 2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 650 | 7 | |a Tamoxifen |2 NLM | |
| 650 | 7 | |a 094ZI81Y45 |2 NLM | |
| 650 | 7 | |a Calreticulin |2 NLM | |
| 700 | 1 | |a Corbizi Fattori, Giuditta |e verfasserin |4 aut | |
| 700 | 1 | |a McKerrell, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Boucher, Rebecca H |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Aimee |e verfasserin |4 aut | |
| 700 | 1 | |a Fletcher, Rachel S |e verfasserin |4 aut | |
| 700 | 1 | |a Forte, Dorian |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Jose-Ezequiel |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, James |e verfasserin |4 aut | |
| 700 | 1 | |a Glover, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Erica |e verfasserin |4 aut | |
| 700 | 1 | |a Bridges, Hannah R |e verfasserin |4 aut | |
| 700 | 1 | |a Grassi, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Meira, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Mead, Adam J |e verfasserin |4 aut | |
| 700 | 1 | |a Knapper, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Ewing, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Butt, Nauman M |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Francis, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, Fiona J |e verfasserin |4 aut | |
| 700 | 1 | |a Coppell, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a McMullin, Mary F |e verfasserin |4 aut | |
| 700 | 1 | |a Wadelin, Frances |e verfasserin |4 aut | |
| 700 | 1 | |a Narayanan, Srinivasan |e verfasserin |4 aut | |
| 700 | 1 | |a Milojkovic, Dragana |e verfasserin |4 aut | |
| 700 | 1 | |a Drummond, Mark W |e verfasserin |4 aut | |
| 700 | 1 | |a Sekhar, Mallika |e verfasserin |4 aut | |
| 700 | 1 | |a ElDaly, Hesham |e verfasserin |4 aut | |
| 700 | 1 | |a Hirst, Judy |e verfasserin |4 aut | |
| 700 | 1 | |a Paramor, Maike |e verfasserin |4 aut | |
| 700 | 1 | |a Baxter, E Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Godfrey, Anna L |e verfasserin |4 aut | |
| 700 | 1 | |a Harrison, Claire N |e verfasserin |4 aut | |
| 700 | 1 | |a Méndez-Ferrer, Simón |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 14(2023), 1 vom: 25. Nov., Seite 7725 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:25 |g month:11 |g pages:7725 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-023-43175-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 1 |b 25 |c 11 |h 7725 | ||